Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis

Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis

PurposeTo explore the risk of stroke (including ischemic and hemorrhagic stroke) in type 2 diabetes mellitus treated with glucagon-like peptide 1 receptor agonist (GLP-1RA) medication according to data from the Cardiovascular Outcome Trials(CVOT).MethodsRandomized controlled trials (RCT) on GLP-1RA...

Full description

Bibliographic Details
Main Authors:	Jinjing Wei, Bing Yang, Ruxin Wang, Haowen Ye, Ying Wang, Lihong Wang, Xiaofang Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Endocrinology
Subjects:	ischemic stroke stroke T2DM GLP-1RA CVOTs (cardiovascular outcome trials)
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2022.1007980/full

Similar Items

Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics
by: Ildiko Lingvay, et al.
Published: (2023-02-01)

The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials
by: Meixin Yu, et al.
Published: (2023-07-01)

High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist
by: Bingwei Ma, et al.
Published: (2023-06-01)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
by: Panagiotis I. Georgianos, et al.
Published: (2022-02-01)

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS
by: Zheng Yang, et al.
Published: (2022-10-01)

Berberine enhances the function of db/db mice islet β cell through GLP-1/GLP-1R/PKA signaling pathway in intestinal L cell and islet α cell
by: Wenbin Wu, et al.
Published: (2023-07-01)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
by: Apurva Khedagi, et al.
Published: (2023-03-01)

Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis
by: Congqin Chen, et al.
Published: (2023-01-01)

G Protein-Coupled Receptor 40 Agonist LY2922470 Alleviates Ischemic-Stroke-Induced Acute Brain Injury and Functional Alterations in Mice
by: Yingyu Lu, et al.
Published: (2023-07-01)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
by: Ana Petrovic, et al.
Published: (2023-05-01)

Citicoline for ischemic stroke: ICTUS trial
by: Vladimir Anatolyevich Parfenov
Published: (2012-12-01)

GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report
by: Fionnuala Crowley, et al.
Published: (2024-04-01)

GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment
by: Justin Wan, et al.
Published: (2024-02-01)

HADH may be the target molecule of early vascular endothelial impairment in T2DM
by: Haowen Ye, et al.
Published: (2022-08-01)

Effects of Acupuncture in Ischemic Stroke Rehabilitation: A Randomized Controlled Trial
by: Lixia Li, et al.
Published: (2022-06-01)

The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review
by: Ioanna Daniilopoulou, et al.
Published: (2022-02-01)

Advancements in diagnostic and interventional radiology for stroke treatment: the path from trial to bedside through the pre-MR CLEAN, MR CLEAN, and MR CLEAN II eras
by: Noor Samuels, et al.
Published: (2024-01-01)

Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis
by: Alhassane Diallo, et al.
Published: (2022-12-01)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
by: Han Na Jung, et al.
Published: (2022-05-01)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
by: Maria Mirabelli, et al.
Published: (2021-03-01)

Abstract 1122‐000221: High School Student Stroke Awareness in Rio De Janeiro
by: Avani Gireesha
Published: (2021-11-01)

Comparison of routine hematological indicators of liver and kidney function, blood count and lipid profile in healthy people and stroke patients
by: Xiaofang Cui, et al.
Published: (2020-02-01)

Abstract 1122‐000126: Mobile Stroke Unit Process Metrics in Large Vessel Occlusion Stroke Patients: BEST‐MSU Substudy
by: Alexandra L Czap, et al.
Published: (2021-11-01)

Abstract 1122‐000205: Bilateral ACA Stroke ‐ A Case Report of an Unusual Presentation
by: Tejeswi Suryadevara, et al.
Published: (2021-11-01)

Factors Associated With Premature Termination of Hyperacute Stroke Trials: A Review
by: Yasmin N. Aziz, et al.
Published: (2024-04-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Neff LM
Published: (2010-07-01)

Thrombectomy in Childhood Stroke
by: Peter B. Sporns, et al.
Published: (2019-03-01)

Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system
by: Sarina Gadgaard, et al.
Published: (2023-04-01)

Monogenic Causes of Strokes
by: Justyna Chojdak-Łukasiewicz, et al.
Published: (2021-11-01)

Oncologic Diseases as a Risk Factor for Cryptogenic Stroke
by: G. R. Ramazanov, et al.
Published: (2022-01-01)

Biomarkers and the outcomes of ischemic stroke
by: Ying Huang, et al.
Published: (2023-06-01)

HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity
by: P.P. Mohanan, et al.
Published: (2023-01-01)

Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
by: André J. Scheen
Published: (2024-01-01)

Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study
by: Tsung-Kun Lin, et al.
Published: (2022-08-01)

Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes
by: Clara Luna-Marco, et al.
Published: (2023-10-01)

Genetic insights into the risk of snoring on stroke and ischemic stroke: A single-variable and multivariable Mendelian randomization
by: Qiang He, et al.
Published: (2022-12-01)

Evaluating Age, Sex, Racial, and Ethnic Representation in Acute Ischemic Stroke Trials, 2010 to 2020: A Systematic Review and Meta‐Analysis
by: Emily K. Acton, et al.
Published: (2022-04-01)

Ischemic stroke as a rare cause of seizures in a newborn – case report
by: Karolina Widłak, et al.
Published: (2019-07-01)

Abstract 1122‐000242: Effect of Covid‐19 on Stroke Treatment in Australia and New Zealand
by: Ela Machiroutu
Published: (2021-11-01)

Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
by: Melanie J. Davies, et al.
Published: (2022-08-01)